Literature DB >> 20413683

An extensive invasive intracranial human glioblastoma xenograft model: role of high level matrix metalloproteinase 9.

Yunge Zhao1, Aizhen Xiao, Charles G diPierro, Joan E Carpenter, Rana Abdel-Fattah, Gerard T Redpath, Maria-Beatriz S Lopes, Isa M Hussaini.   

Abstract

The lack of an intracranial human glioma model that recapitulates the extensive invasive and hypervascular features of glioblastoma (GBM) is a major hurdle for testing novel therapeutic approaches against GBM and studying the mechanism of GBM invasive growth. We characterized a high matrix metalloproteinase-9 (MMP-9) expressing U1242 MG intracranial xenograft mouse model that exhibited extensive individual cells and cell clusters in a perivascular and subpial cellular infiltrative pattern, geographic necrosis and infiltrating tumor-induced vascular proliferation closely resembling the human GBM phenotype. MMP-9 silencing cells with short hairpin RNA dramatically blocked the cellular infiltrative pattern, hypervascularity, and cell proliferation in vivo, and decreased cell invasion, colony formation, and cell motility in vitro, indicating that a high level of MMP-9 plays an essential role in extensive infiltration and hypervascularity in the xenograft model. Moreover, epidermal growth factor (EGF) failed to stimulate MMP-9 expression, cell invasion, and colony formation in MMP-9-silenced clones. An EGF receptor (EGFR) kinase inhibitor, a RasN17 dominant-negative construct, MEK and PI3K inhibitors significantly blocked EGF/EGFR-stimulated MMP-9, cell invasion, and colony formation in U1242 MG cells, suggesting that MMP-9 is involved in EGFR/Ras/MEK and PI3K/AKT signaling pathway-mediated cell invasion and anchorage-independent growth in U1242 MG cells. Our data indicate that the U1242 MG xenograft model is valuable for studying GBM extensive invasion and angiogenesis as well as testing anti-invasive and anti-angiogenic therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413683      PMCID: PMC2877863          DOI: 10.2353/ajpath.2010.090571

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  69 in total

1.  Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck.

Authors:  Alessandro Franchi; Marco Santucci; Emanuela Masini; Iacopo Sardi; Milena Paglierani; Oreste Gallo
Journal:  Cancer       Date:  2002-11-01       Impact factor: 6.860

2.  Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy.

Authors:  P Wesseling; J A van der Laak; M Link; H L Teepen; D J Ruiter
Journal:  Hum Pathol       Date:  1998-04       Impact factor: 3.466

3.  Determinants for the establishment of permanent tissue culture lines from human gliomas.

Authors:  B Westermark; J Pontén; R Hugosson
Journal:  Acta Pathol Microbiol Scand A       Date:  1973-11

4.  Expression of PECAM-1/CD31 isoforms in human brain gliomas.

Authors:  F Aroca; W Renaud; C Bartoli; C Bouvier-Labit; D Figarella-Branger
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

5.  [Inhibitory effects of siRNA targeting epidermal growth factor receptor on proliferation and invasion of human glioblastoma cells].

Authors:  Chun-Sheng Kang; Pei-Yu Pu; Guang-Xiu Wang; Yan-He Li; Lun Dong; Hu Wang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2004-09-17

6.  Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.

Authors:  S M Ellerbroek; J M Halbleib; M Benavidez; J K Warmka; E V Wattenberg; M S Stack; L G Hudson
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

7.  Elevated levels of Mr 92,000 type IV collagenase during tumor growth in vivo.

Authors:  R Sawaya; Y Go; A P Kyritisis; J Uhm; B Venkaiah; S Mohanam; Z L Gokaslan; J S Rao
Journal:  Biochem Biophys Res Commun       Date:  1998-10-20       Impact factor: 3.575

8.  Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.

Authors:  Hiroaki Wakimoto; Santosh Kesari; Christopher J Farrell; William T Curry; Cecile Zaupa; Manish Aghi; Toshihiko Kuroda; Anat Stemmer-Rachamimov; Khalid Shah; Ta-Chiang Liu; Deva S Jeyaretna; Jason Debasitis; Jan Pruszak; Robert L Martuza; Samuel D Rabkin
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  Epidermal growth factor differentially regulates low density lipoprotein receptor-related protein gene expression in neoplastic and fetal human astrocytes.

Authors:  I M Hussaini; M D Brown; L R Karns; J Carpenter; G T Redpath; S L Gonias; S R Vandenberg
Journal:  Glia       Date:  1999-01       Impact factor: 7.452

10.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.

Authors:  Naoki Shinojima; Kenji Tada; Shoji Shiraishi; Takanori Kamiryo; Masato Kochi; Hideo Nakamura; Keishi Makino; Hideyuki Saya; Hirofumi Hirano; Jun-Ichi Kuratsu; Koji Oka; Yasuji Ishimaru; Yukitaka Ushio
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

View more
  27 in total

1.  Increased PAI-1 in females compared with males is protective for abdominal aortic aneurysm formation in a rodent model.

Authors:  Paul D DiMusto; Guanyi Lu; Abhijit Ghosh; Karen J Roelofs; Gang Su; Yunge Zhao; Christine L Lau; Omar Sadiq; Brendan McEvoy; Adriana Laser; Jose A Diaz; Thomas W Wakefield; Peter K Henke; Jonathan L Eliason; Gilbert R Upchurch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-02-03       Impact factor: 4.733

Review 2.  Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Matrix Biol       Date:  2015-04-22       Impact factor: 11.583

Review 3.  Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?

Authors:  Lisa Gherardini; Giuseppe Bardi; Mariangela Gennaro; Tommaso Pizzorusso
Journal:  Cell Mol Life Sci       Date:  2013-03-19       Impact factor: 9.261

4.  Glioma-associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline.

Authors:  Feng Hu; Min-Chi Ku; Darko Markovic; Omar Dildar a Dzaye; Seija Lehnardt; Michael Synowitz; Susanne A Wolf; Helmut Kettenmann
Journal:  Int J Cancer       Date:  2014-05-09       Impact factor: 7.396

5.  A novel chronic advanced stage abdominal aortic aneurysm murine model.

Authors:  Guanyi Lu; Gang Su; John P Davis; Basil Schaheen; Emily Downs; R Jack Roy; Gorav Ailawadi; Gilbert R Upchurch
Journal:  J Vasc Surg       Date:  2017-03-06       Impact factor: 4.268

6.  A robust strategy for proteomic identification of biomarkers of invasive phenotype complexed with extracellular heat shock proteins.

Authors:  Steven G Griffiths; Alan Ezrin; Emily Jackson; Lisa Dewey; Alan A Doucette
Journal:  Cell Stress Chaperones       Date:  2019-10-24       Impact factor: 3.667

7.  Dietary phytoestrogens inhibit experimental aneurysm formation in male mice.

Authors:  Guanyi Lu; Gang Su; Yunge Zhao; William F Johnston; Nicholas E Sherman; Emilie F Rissman; Christine Lau; Gorav Ailawadi; Gilbert R Upchurch
Journal:  J Surg Res       Date:  2013-12-03       Impact factor: 2.192

Review 8.  The Unwanted Cell Migration in the Brain: Glioma Metastasis.

Authors:  Xue Tao Qi; Jiang Shan Zhan; Li Ming Xiao; Lina Li; Han Xiao Xu; Zi Bing Fu; Yan Hao Zhang; Jing Zhang; Xi Hua Jia; Guo Ge; Rui Chao Chai; Kai Gao; Albert Cheung Hoi Yu
Journal:  Neurochem Res       Date:  2017-05-06       Impact factor: 3.996

Review 9.  Vertebrate animal models of glioma: understanding the mechanisms and developing new therapies.

Authors:  Leon Chen; Yuqing Zhang; Jingxuan Yang; John P Hagan; Min Li
Journal:  Biochim Biophys Acta       Date:  2013-04-22

Review 10.  The pathobiology of collagens in glioma.

Authors:  Leo S Payne; Paul H Huang
Journal:  Mol Cancer Res       Date:  2013-07-16       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.